17-8-1　ⓔ文献

  1. Kanda J, Saji H, et al: Related transplantation with HLA–1 Ag mismatch in the GVH direction and HLA–8/8 allele–matched unrelated transplantation: a nationwide retrospective study. Blood, 2012; 119: 2409–2416.

  2. Bensinger WI: High–dose preparatory regimens (Appelbaum FR, Forman SJ eds), Blackwell Science, 2009; 316–332.

  3. Stem Cell Trialists’ Collaborative Group: Allogeneic peripheral blood stem–cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta–analysis of nine randomized trials. J Clin Oncol, 2005; 23: 5074–5087.

  4. Filipovich AH, Weisdorf D, et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft–versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 2005; 11: 945–956.

  5. Jagasia MH, Greinix HT, et al: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft–versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant, 2015; 21: 389–401 e1.

  6. Tomblyn M, Chiller T, et al: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant, 2009; 15: 1143–1238.

  7. Freifeld AG, Bow EJ, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 2011; 52: e56–e93.

  8. Socie G, Salooja N, et al: Nonmalignant late effects after allogeneic stem cell transplantation. Blood, 2003; 101: 3373–3385.

  9. Kanda Y, Wada H, et al: Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation. Ann Hematol, 2014; 93: 287–292.

  10. Bosi A, Laszlo D, et al: Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol, 2001; 19: 3675–3684.